Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer

To investigate the relationship between serum PSA level, Gleason score of PCa and the outcomes of Ga(68)-PSMA PET/CT in patients with recurrent PCa.

A total of 109 consecutive patients (median age 71 years; range 48-89 years) who had PSA recurrence after RP and/or hormonotherapy and/or radiotherapy were included in this study. Local recurrences, lymph node metastasis (pelvic, abdominal and/or supradiaphragmatic), bone metastases (oligometastatic/multimetastatic) and other metastatic sites (lung, liver, brain, etc) were documented.

In 91(83.4%) patients at least one lesion characteristic for PCa was detected by(68)Ga-PSMA PET/CT. The median serum total PSA (tPSA) was 6.5 (0.2-640) ng/ml.There was a significant difference between (68)Ga-PSMA PET/CT positive and negative patients in terms of serum total PSA value. No statistical significance was found between positive and negative (68)Ga-PSMA PET/CT findings in terms of Gleason score. Local recurrence was detected in 56 patients. whereas lymph node metastases were demonstrated in 46 patients. Pelvic nodal disease was the most frequent presentation followed by abdominal and supradiaphragmaticnodal involvement. Bone metastases [oligometastasis, (n = 20); multimetastasis, (n = 35)⦌ were also detected in 55 patients. In the ROC analysis for the study cohort, the optimal cut-off value of total serum PSA was determined as 0.67 ng/ml for distinguishing between positive and negative (68)Ga-PSMA PET/CT images, with an area under curve of 0.952 (95% CI 0.911-0.993).

(68)Ga-PSMA PET/CT was found to be an effective tool for the detection of recurrent PCa. Even though no relationship was detected between the GS and (68)Ga-PSMA PET/CT findings, serum total PSA values may be used for estimating the likelihood of positive (68)Ga-PSMA PET/CT results.

Annals of nuclear medicine. 2017 Sep 12 [Epub ahead of print]

Yasemin Sanli, Serkan Kuyumcu, Oner Sanli, Fikret Buyukkaya, Ayça İribaş, Goksel Alcin, Emin Darendeliler, Yasemin Ozluk, Sevda Ozel Yildiz, Cüneyt Turkmen

Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Ic Hastalıkları Binasi, Nukleer Tip Anabilim Dali, Istanbul, Turkey. ., Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Ic Hastalıkları Binasi, Nukleer Tip Anabilim Dali, Istanbul, Turkey., Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey., Faculty of Health Science, Istanbul University, Istanbul, Turkey., Department of Radiation Oncology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey., Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey., Department of Biostatistics and Medical Informatics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe